Login / Signup
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.
Akihiko Inoue
Shutaro Isokawa
Norio Otani
Shinichi Ishimatsu
Published in:
Critical care (London, England) (2020)
Keyphrases
</>
sars cov
combination therapy